FDA Clearance Tracker · P990027-S010
BAUSCH & LOMB TECHNOLAS T217Z ZYOPTIX LASER SYSTEM
Last checked: Nov 20, 2026Latest source record: May 18, 2010 (this decision)Source: openFDAMethods & limitations
Decided
May 18, 2010
Approved
Time to decision
645 days
Received Aug 11, 2008. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P990027-S010
- Device name
- BAUSCH & LOMB TECHNOLAS T217Z ZYOPTIX LASER SYSTEM
- Applicant
- Technolas Perfect Vision GmbH
- Applicant location
- MüNchen
- Received
- Aug 11, 2008
- Decided
- May 18, 2010
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P990027
Device type
- Device type
- Excimer laser system (LZS)
- Device class
- Class III
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE FOLLOWING CHANGES: 1) REMOVAL OF A REDUNDANT FLUENCE TEST;2) INTRODUCTION OF A NEW SCANNER SYSTEM FROM GSI TO THE LASER SYSTEM:3) EXTRAPOLATION OF THE WAVEFRONT DATA IN THE DIAGNOSTIC ZYWAVE SOFTWARE;4) NEW ZRS (ZYOPTIX REMOTE SUPPORT) SOFTWARE TO MONITOR THE PERFORMANCE OF THELASER AND DIAGNOSTIC DEVICES REMOTELY VIA THE INTERNET;5) MODIFICATION OF THE ZRS TO INCLUDE TRULINK, AN ENHANCEMENT TO THE ZRS SYSTEM;6) INTRODUCTION OF A NEW OP FIELD ILLUMINATION IN THE LASER SYSTEM;7) CHANGE OF THE VIDEO CHIP IN THE CCD LENSLET CAMERA DMK4002-IR; AND8) CHANGE IN THE SUPPLIER OF THE TEMPERATURE CONTROL UNIT IN THE LASER SYSTEM.
Source documents
Other decisions for Technolas Perfect Vision GmbH
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- TECHNOLAS TENEO 317 (MODEL 2) Excimer Laser SystemPMA supplement
P990027-S021 · Decided Nov 22, 2023 · 293 days after receipt · Panel Track
Device type: Excimer laser system (LZS) · Ophthalmology
4 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.